Developer docs
API playgroundTry for free, no card

Search company profiles

PL Developments

Full company profile

uuid0000oi3

Namestring
PL Developments
Legal namestring
P&L Development, LLC
Company typeenum
Private
Founded yearint
1988
Descriptiontext

PL Developments (P&L Development, LLC) is a privately held, family-controlled manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer healthcare goods founded in 1988 and headquartered in Westbury, New York. The company operates as a B2B private-label platform serving major U.S. retailers — including a dedicated relationship with Walmart and Sam's Club — producing store-brand equivalents of national brand OTC products across nine categories: allergy, analgesics, cough/cold, digestive, first aid, nicotine replacement therapy, personal care, sleep, and nutritional/OTC drug gummies. Its portfolio spans 2,000+ unique SKUs and 450+ products, with PLD manufacturing private label products at 30-80% cost savings versus national brand equivalents.

The company's technical platform comprises 2.5M+ sq. ft. of FDA-registered, cGMP-compliant facilities across New York, Florida, California, and South Carolina, with annual production capacity of 5B+ solid dosage units, 3B+ liquid dosage units, and 1B+ gummies. Key technical differentiators include a starchless gummy manufacturing process with four dedicated production lines, the only FDA-approved nicotine chewing gum operation in the U.S. (one of three globally), and 40+ approved and pending ANDAs acquired from Teva Pharmaceuticals' U.S. store-brand drug portfolio in 2019. The company also operates PLD Pharma Services as a Contract Development and Manufacturing Organization (CDMO) providing formulation development, regulatory expertise, manufacturing, and packaging for pharmaceutical clients.

PL Developments generates revenue through three streams: (1) private-label manufacturing under retailer store brands, (2) contract development and manufacturing services via PLD Pharma Services, and (3) contract packaging services. Pricing is negotiated through direct sales relationships rather than publicly disclosed. In May 2026, the company divested its U.S. gummy manufacturing operations to TopGum Industries Ltd. for up to USD 35 million, retaining a strategic commercial partnership to distribute TopGum products under store-brand labels. The company is led by founder Mitch Singer (CEO), with family members Evan Singer as President, Adam Singer as Chief Expansion & Logistics Officer, and Linda Singer as Executive VP of Creative Services, alongside a senior leadership team drawn from Teva Pharmaceuticals, P&G, Banner Pharmacaps, and The Nature's Bounty Co.

Short descriptiontext

PL Developments is a privately held, family-owned manufacturer and distributor of private-label OTC pharmaceuticals and consumer healthcare goods, serving major U.S. retailers across nine categories from FDA-registered, cGMP-compliant facilities in four states.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersWestbury, United States
HQ citystring
Westbury
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private label OTC pharmaceuticals, contract development manufacturing, consumer healthcare packaging, pharmaceutical manufacturing services, store brand OTC products
Industry4 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Drugs and Druggists' Sundries Merchant Wholesalers4242
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Private Label OTC Pharmaceutical Manufacturing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Private Label Manufacturing
TypeOne Time License
Description

PLD manufactures, packages and distributes over-the-counter pharmaceutical products and consumer healthcare goods under store-brand labels for major retailers. The company creates products for brands consumers know through private label programs.

pldevelopments.com
2Contract Development and Manufacturing (CDMO)
TypeProfessional Services
Description

PLD Pharma Services provides end-to-end contract development and manufacturing solutions for pharmaceutical and consumer health products, including R&D support, extra manufacturing capacity, and turnkey solutions for liquid and solid dose delivery systems.

pldpharma.com
3Contract Packaging
TypeProfessional Services
Description

PLD offers contract packaging services to major OTC and nutritional companies, providing packaging capabilities including bottling, blistering, cartoning, pouching, clamshell, twinpacks, and vial packs.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PL Developments manufactures, packages, and distributes over-the-counter (OTC) pharmaceutical products and consumer healthcare goods, primarily under store-brand/private-label programs for major retailers such as Walmart and Sam's Club. The company operates an integrated platform spanning product development, manufacturing, packaging, distribution, creative services, sales/marketing, and quality/regulatory across 2+ million square feet of FDA-registered, cGMP-compliant facilities. It also runs PLD Pharma Services as a Contract Development and Manufacturing Organization (CDMO) for pharmaceutical clients seeking R&D support, manufacturing capacity, or turnkey solutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 30-80% cost savings compared to brand-name drugs
+3 more records
Product overview1 text field

PL Developments (PLD) is a manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer healthcare goods operating as a platform of integrated capabilities. The company's core product portfolio includes private label OTC products across nine categories: Allergy (Allegra, Claritin, Zyrtec generics), Analgesics (Advil, Aleve, Tylenol generics), Cough/Cold (Mucinex, Dayquil, Nyquil generics), Digestive (Colace, Gas-X, Pepto Bismol generics), First Aid (alcohol, Epsom salt), Nicotine Replacement Therapy (Nicorette gum and lozenges), Nutritional/OTC Drug Gummies (melatonin, vitamins), Personal Care (Abreva, Differin, Rogaine generics), and Sleep (Unisom, ZzzQuil generics). These products are manufactured through PLD's integrated service platform comprising Product Development, Manufacturing (solid dose, liquid dose, gummy production), Packaging, Distribution/Warehouse, Creative Services, Sales and Marketing, and Quality and Regulatory Services. The company also operates PLD Pharma Services as a Contract Development and Manufacturing Organization (CDMO) for pharmaceutical clients. All operations are conducted in FDA-registered, cGMP-compliant facilities spanning over 2 million square feet across New York, Florida, California, and South Carolina.

Product and service1 record
1Allergy Products
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Following TopGum's acquisition of PLD's U.S. gummy manufacturing operations for up to USD 35 million, PLD secured a strategic commercial partnership to distribute TopGum products to major U.S. retailers under store-brand labels. The transaction gives TopGum its first U.S.-based FDA pharmaceutical-compliant manufacturing platform while PLD gains privileged access to TopGum's global portfolio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

PLD partnered with Amneal to launch the first store brand of Diclofenac Sodium Topical Gel 1%, the compare-to product of Voltaren arthritis pain relief gel. This partnership expanded PLD's topical analgesic portfolio.

Recent move17 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Perrigo is the largest U.S. private label and OTC manufacturer with comparable store-brand product lines across analgesics, cough/cold, digestive, and NRT categories serving the same mass retail customers as PL Developments.

TypeDirect peer
Description

Amneal is a generic and specialty pharmaceutical manufacturer that partnered with PLD on first store-brand diclofenac gel and directly competes in private-label and OTC generics manufacturing.

TypeDirect peer
Description

Apotex is a major global generics manufacturer with significant OTC and store-brand product overlap, competing for the same retail private-label contracts and pharmacy supply relationships.

TypeBroad incumbent
Description

Catalent is a leading global CDMO offering development, manufacturing, and packaging services across solid, liquid, and specialty dosage forms, competing with PLD Pharma Services for third-party pharma manufacturing contracts.

TypeBroad incumbent
Description

Patheon, now part of Thermo Fisher, is one of the largest global CDMOs offering formulation, manufacturing, and packaging services directly competitive with PLD Pharma Services across small-molecule dosage forms.

TypeBroad incumbent
Description

Teva sold its U.S. store-brand drug portfolio to PLD in 2019 but remains a peer in generic and OTC pharmaceuticals with overlapping ANDA portfolios and private-label customer relationships.

TypeBroad incumbent
Description

Church & Dwight operates in OTC personal care and consumer health with branded products (e.g., Batiste, Orajel) in categories adjacent to PLD's personal care store-brand portfolio, sharing major retail customers.

TypeEmerging player
Description

TopGum acquired PLD's U.S. gummy manufacturing operations in May 2026 and is now a strategic partner, with an emerging U.S. FDA-compliant gummy platform overlapping the nutritional and OTC gummy category.

9McKesson Corporation
TypeRegional player
Description

McKesson is a major U.S. pharmaceutical wholesaler and distributor; while not a manufacturer, it operates in adjacent drug distribution and pharmacy supply services and shares major retail pharmacy customers with PLD.

TypeOthers
Description

Topco is a member-owned buying cooperative for retail and wholesale grocers that supports private label programs and is a potential counterpart/aggregator for store-brand OTC categories served by PLD.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PL Developments

Private Label OTC Pharmaceutical Manufacturingpldevelopments.com

PL Developments is a privately held, family-owned manufacturer and distributor of private-label OTC pharmaceuticals and consumer healthcare goods, serving major U.S. retailers across nine categories from FDA-registered, cGMP-compliant facilities in four states.

What PL Developments does

PL Developments (P&L Development, LLC) is a privately held, family-controlled manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer healthcare goods founded in 1988 and headquartered in Westbury, New York. The company operates as a B2B private-label platform serving major U.S. retailers — including a dedicated relationship with Walmart and Sam's Club — producing store-brand equivalents of national brand OTC products across nine categories: allergy, analgesics, cough/cold, digestive, first aid, nicotine replacement therapy, personal care, sleep, and nutritional/OTC drug gummies. Its portfolio spans 2,000+ unique SKUs and 450+ products, with PLD manufacturing private label products at 30-80% cost savings versus national brand equivalents.

The company's technical platform comprises 2.5M+ sq. ft. of FDA-registered, cGMP-compliant facilities across New York, Florida, California, and South Carolina, with annual production capacity of 5B+ solid dosage units, 3B+ liquid dosage units, and 1B+ gummies. Key technical differentiators include a starchless gummy manufacturing process with four dedicated production lines, the only FDA-approved nicotine chewing gum operation in the U.S. (one of three globally), and 40+ approved and pending ANDAs acquired from Teva Pharmaceuticals' U.S. store-brand drug portfolio in 2019. The company also operates PLD Pharma Services as a Contract Development and Manufacturing Organization (CDMO) providing formulation development, regulatory expertise, manufacturing, and packaging for pharmaceutical clients.

PL Developments generates revenue through three streams: (1) private-label manufacturing under retailer store brands, (2) contract development and manufacturing services via PLD Pharma Services, and (3) contract packaging services. Pricing is negotiated through direct sales relationships rather than publicly disclosed. In May 2026, the company divested its U.S. gummy manufacturing operations to TopGum Industries Ltd. for up to USD 35 million, retaining a strategic commercial partnership to distribute TopGum products under store-brand labels. The company is led by founder Mitch Singer (CEO), with family members Evan Singer as President, Adam Singer as Chief Expansion & Logistics Officer, and Linda Singer as Executive VP of Creative Services, alongside a senior leadership team drawn from Teva Pharmaceuticals, P&G, Banner Pharmacaps, and The Nature's Bounty Co.

PL Developments firmographics

Firmographics
Name
PL Developments
Legal name
P&L Development, LLC
Website
https://pldevelopments.com
Company type
Private
Founded year
1988
Operating status
Operating
Headcount range
501–1,000 employees
Short description
PL Developments is a privately held, family-owned manufacturer and distributor of private-label OTC pharmaceuticals and consumer healthcare goods, serving major U.S. retailers across nine categories from FDA-registered, cGMP-compliant facilities in four states.
Ownership category
akta.pro rank

PL Developments industry classification

Industry
Product category
Private Label OTC Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (4242)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Private label OTC pharmaceuticals
  • Contract development manufacturing
  • Consumer healthcare packaging
  • Pharmaceutical manufacturing services
  • Store brand OTC products

Where PL Developments is headquartered

Location

Headquarters

HQ city
Westbury
HQ country
United States
HQ region
North America

Offices7 records

Markets served

PL Developments business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

  1. Private Label Manufacturing: PLD manufactures, packages and distributes over-the-counter pharmaceutical products and consumer healthcare goods under store-brand labels for major retailers. The company creates products for brands consumers know through private label programs.
  2. Contract Development and Manufacturing (CDMO): PLD Pharma Services provides end-to-end contract development and manufacturing solutions for pharmaceutical and consumer health products, including R&D support, extra manufacturing capacity, and turnkey solutions for liquid and solid dose delivery systems.
  3. Contract Packaging: PLD offers contract packaging services to major OTC and nutritional companies, providing packaging capabilities including bottling, blistering, cartoning, pouching, clamshell, twinpacks, and vial packs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

PL Developments product offering

Product offering

Core offering

PL Developments manufactures, packages, and distributes over-the-counter (OTC) pharmaceutical products and consumer healthcare goods, primarily under store-brand/private-label programs for major retailers such as Walmart and Sam's Club. The company operates an integrated platform spanning product development, manufacturing, packaging, distribution, creative services, sales/marketing, and quality/regulatory across 2+ million square feet of FDA-registered, cGMP-compliant facilities. It also runs PLD Pharma Services as a Contract Development and Manufacturing Organization (CDMO) for pharmaceutical clients seeking R&D support, manufacturing capacity, or turnkey solutions.

Product overview

PL Developments (PLD) is a manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer healthcare goods operating as a platform of integrated capabilities. The company's core product portfolio includes private label OTC products across nine categories: Allergy (Allegra, Claritin, Zyrtec generics), Analgesics (Advil, Aleve, Tylenol generics), Cough/Cold (Mucinex, Dayquil, Nyquil generics), Digestive (Colace, Gas-X, Pepto Bismol generics), First Aid (alcohol, Epsom salt), Nicotine Replacement Therapy (Nicorette gum and lozenges), Nutritional/OTC Drug Gummies (melatonin, vitamins), Personal Care (Abreva, Differin, Rogaine generics), and Sleep (Unisom, ZzzQuil generics). These products are manufactured through PLD's integrated service platform comprising Product Development, Manufacturing (solid dose, liquid dose, gummy production), Packaging, Distribution/Warehouse, Creative Services, Sales and Marketing, and Quality and Regulatory Services. The company also operates PLD Pharma Services as a Contract Development and Manufacturing Organization (CDMO) for pharmaceutical clients. All operations are conducted in FDA-registered, cGMP-compliant facilities spanning over 2 million square feet across New York, Florida, California, and South Carolina.

Differentiator

Problem solved

Functional benefit

Products and services

  • Allergy Products

Quantifiable outcome

  • 30-80% cost savings compared to brand-name drugs
  • +3 more outcomes

Companies that use PL Developments

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

PL Developments technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PL Developments partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • TopGum Industries Ltd.coreStrategic or Co-development Partner · 5 May 2026Following TopGum's acquisition of PLD's U.S. gummy manufacturing operations for up to USD 35 million, PLD secured a strategic commercial partnership to distribute TopGum products to major U.S. retailers under store-brand labels. The transaction gives TopGum its first U.S.-based FDA pharmaceutical-compliant manufacturing platform while PLD gains privileged access to TopGum's global portfolio.
  • Amneal PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2020PLD partnered with Amneal to launch the first store brand of Diclofenac Sodium Topical Gel 1%, the compare-to product of Voltaren arthritis pain relief gel. This partnership expanded PLD's topical analgesic portfolio.

Scale indicators11 records

Recent moves17 records

Expansion highlights6 records

PL Developments competitors and assessment

Company assessment

Direct peers

  • Perrigo Company: Perrigo is the largest U.S. private label and OTC manufacturer with comparable store-brand product lines across analgesics, cough/cold, digestive, and NRT categories serving the same mass retail customers as PL Developments.
  • Amneal Pharmaceuticals: Amneal is a generic and specialty pharmaceutical manufacturer that partnered with PLD on first store-brand diclofenac gel and directly competes in private-label and OTC generics manufacturing.
  • Apotex Inc. Apotex is a major global generics manufacturer with significant OTC and store-brand product overlap, competing for the same retail private-label contracts and pharmacy supply relationships.

Broad incumbents

  • Catalent (Novo Holdings): Catalent is a leading global CDMO offering development, manufacturing, and packaging services across solid, liquid, and specialty dosage forms, competing with PLD Pharma Services for third-party pharma manufacturing contracts.
  • Thermo Fisher Scientific (Patheon): Patheon, now part of Thermo Fisher, is one of the largest global CDMOs offering formulation, manufacturing, and packaging services directly competitive with PLD Pharma Services across small-molecule dosage forms.
  • Teva Pharmaceutical Industries: Teva sold its U.S. store-brand drug portfolio to PLD in 2019 but remains a peer in generic and OTC pharmaceuticals with overlapping ANDA portfolios and private-label customer relationships.
  • Church & Dwight: Church & Dwight operates in OTC personal care and consumer health with branded products (e.g., Batiste, Orajel) in categories adjacent to PLD's personal care store-brand portfolio, sharing major retail customers.

Emerging players

  • TopGum Industries Ltd. TopGum acquired PLD's U.S. gummy manufacturing operations in May 2026 and is now a strategic partner, with an emerging U.S. FDA-compliant gummy platform overlapping the nutritional and OTC gummy category.

Regional players

  • McKesson Corporation: McKesson is a major U.S. pharmaceutical wholesaler and distributor; while not a manufacturer, it operates in adjacent drug distribution and pharmacy supply services and shares major retail pharmacy customers with PLD.

Others

  • Topco Associates: Topco is a member-owned buying cooperative for retail and wholesale grocers that supports private label programs and is a potential counterpart/aggregator for store-brand OTC categories served by PLD.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

PL Developments social profiles

Digital presence

PL Developments compliance and trust

Trust signal

Compliance9 records

PL Developments financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PL Developments leadership team

Management profile

Number of profiles

Profiles16 records

PL Developments subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

PL Developments funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PL Developments M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PL Developments

What does PL Developments do?

PL Developments manufactures, packages, and distributes over-the-counter (OTC) pharmaceutical products and consumer healthcare goods, primarily under store-brand/private-label programs for major retailers such as Walmart and Sam's Club. The company operates an integrated platform spanning product development, manufacturing, packaging, distribution, creative services, sales/marketing, and quality/regulatory across 2+ million square feet of FDA-registered, cGMP-compliant facilities. It also runs PLD Pharma Services as a Contract Development and Manufacturing Organization (CDMO) for pharmaceutical clients seeking R&D support, manufacturing capacity, or turnkey solutions.

Is PL Developments a public or private company?

PL Developments is a private company. It is classified as family owned and is currently operating.

When was PL Developments founded?

PL Developments was founded in 1988. It employs 501 to 1,000 people.

Where is PL Developments based?

PL Developments is headquartered in Westbury, United States, in the North America region.

How does PL Developments make money?

Three revenue lines are on record. Private Label Manufacturing is the primary driver. The others are contract Development and Manufacturing (CDMO) and contract Packaging.

Who are PL Developments's main competitors?

Direct peers on record are Perrigo Company, Amneal Pharmaceuticals and Apotex Inc.. Broad incumbents are Catalent (Novo Holdings), Thermo Fisher Scientific (Patheon), Teva Pharmaceutical Industries and Church & Dwight. TopGum Industries Ltd. is listed as an emerging player. McKesson Corporation is listed as a regional player. Topco Associates is listed as an others.

Does PL Developments have an API?

No public API is recorded for PL Developments.

What industry is PL Developments in?

PL Developments's product category is Private Label OTC Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWirePL Developments Builds a Smarter, Healthier Supply Chain with KinaxisPL Developments selected Kinaxis Maestro to replace manual planning tools and spreadsheets, aiming to accelerate delivery of healthcare products to major U.S. retailers. The AI-powered platform provides real-time visibility and predictive planning to handle growing consumer demand. PLD supplies Walmart, Walgreens, CVS, Costco, Sam's Club, and Target.TrendHunter.comRecycled Multipack HandlesPakTech partnered with PL Developments to supply automated handle applicators and 100% recycled bottle handles for multipack packaging at its South Carolina facility. The financing arrangement spreads costs across future handle purchases, reducing upfront capital. The recycled handles helped the facility achieve landfill-free status.PR NewswireTopGum Continues Its Rapid Growth Trend and Opens 2026 with Another Record QuarterTopGum Industries Ltd. reported record Q1 2026 financial results with revenues of $31.9 million, an 85% increase year-over-year, driven by a 162% surge in the dietary supplements segment. Adjusted EBITDA grew 112% to $5.3 million, and the company's order backlog reached a record $52 million for the next 4-5 months. Following the reporting period, TopGum completed the acquisition of gummy manufacturing operations in the US from P&L Developments, marking its entry into the pharmaceutical gummy sector and strengthening its presence in its primary target market.PR NewswireTopGum Completes U.S. Acquisition of PL Developments Valued at Up to USD 35 MillionTopGum Industries Ltd. completed its acquisition of P&L Developments' U.S. gummy manufacturing operations for up to USD 35 million, consisting of US$10 million in cash, approximately US$8 million in shares, and up to US$17 million in contingent consideration tied to milestones. The transaction gives TopGum its first U.S.-based FDA pharmaceutical-compliant manufacturing platform and establishes it as a pioneer in the emerging pharmaceutical gummy market, while PLD gains privileged access to TopGum's global portfolio. The acquired operation is expected to generate low single-digit millions in 2026 revenue with negative EBITDA of US$2-3 million during integration, with pharmaceutical gummy products targeted for commercial launch in 2027-2028 under a major unnamed pharmaceutical partner's brands.MorningstarTopGum Completes U.S. Acquisition of PL Developments Valued at Up to USD 35 MillionTopGum Industries Ltd. completed its acquisition of P&L Developments LLC's U.S. gummy manufacturing operations for up to USD 35 million, comprising $10 million in cash, approximately $8 million in shares, and up to $17 million in contingent milestone-based consideration. The transaction gives TopGum its first U.S.-based FDA-compliant manufacturing platform capable of producing pharmaceutical gummies, while PLD secures a strategic commercial partnership to distribute TopGum products to major U.S. retailers under store-brand labels. TopGum expects 2026 to be a transition year with the acquired operation contributing low single-digit millions in revenue and a negative EBITDA of approximately $2 to $3 million, with full earnings power anticipated in subsequent years.YahooPL Developments Builds a Smarter, Healthier Supply Chain with KinaxisPL Developments selected Kinaxis Maestro to replace manual planning tools and spreadsheets, aiming to accelerate delivery of healthcare products to major U.S. retailers. The AI-powered platform provides real-time visibility and predictive planning to handle growing consumer demand. PLD supplies retailers including Walmart, Walgreens, CVS, Costco, Sam's Club, and Target.YahooPL Developments Announces FDA Approval for Omeprazole OTC ANDA and Successful Corporate Debt RefinancingPL Developments announced FDA approval for its Omeprazole Magnesium Tablet OTC ANDA, making it the only US producer, and completed a debt exchange of $350 million in old notes for $368.55 million in new notes. The company expects commercial shipments in early 2025.BenzingaPL Developments Announces FDA Approval for Omeprazole OTC ANDA and Successful Corporate Debt RefinancingPL Developments announced FDA approval for its Omeprazole Magnesium OTC ANDA, making it the only US producer, and completed refinancing of $350 million in senior notes into $368.55 million in new notes. Commercial shipments are expected in early 2025, and the company also plans a concurrent financing of $131.45 million.PR NewswirePL Developments Announces FDA Approval for Omeprazole OTC ANDA and Successful Corporate Debt RefinancingPL Developments announced FDA approval for its Omeprazole Magnesium Tablet OTC ANDA, making it the only US producer, and completed a debt exchange of $350 million in old notes for $368.55 million in new notes. The company expects commercial shipments in early 2025.PR NewswireTricorBraun Acts as an Extension of PL Developments' Procurement TeamTricorBraun has been operating a Vendor Managed Inventory (VMI) program with PL Developments (PLD), a leading FDA-approved pharmaceutical and nutritional products supplier, since approximately 2011, evolving into a strategic extension of PLD's procurement and supply chain team. Over the five-year partnership, TricorBraun has tripled PLD's cost savings and tripled their business volume, including absorbing an acquisition in 2013 that doubled PLD's operations, while managing over two dozen suppliers and increasing managed components from 65 to more than 140. The collaborative program provides just-in-time delivery, global sourcing of materials, and continuous cost optimization, allowing PLD to maintain a lean internal replenishment team while scaling operations.